Background Alpha-1 antitrypsin deficiency (AATD) is a genetic condition that causes early onset pulmonary emphysema and airways obstruction. The complete mechanisms via which AATD causes lung disease are not fully understood. To improve our understanding of the pathogenesis of AATD, we investigated gene expression profiles of bronchoalveolar lavage (BAL) and peripheral blood mononuclear cells (PBMCs) in AATD individuals.
Methods We performed RNA-Seq on RNA extracted from matched BAL and PBMC samples isolated from 89 subjects enrolled in the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) study. Subjects were stratified by genotype and augmentation therapy. Supervised and unsupervised differential gene expression analyses were performed using Weighted Gene Co-expression Network Analysis (WGCNA) to identify gene profiles associated with subjects’ clinical variables. The genes in the most significant WGCNA module were used to cluster AATD individuals. Gene validation was performed by NanoString nCounter Gene Expression Assay.
Result We observed modest effects of AATD genotype and augmentation therapy on gene expression. When WGCNA was applied to BAL transcriptome, one gene module, ME31 (2312 genes), correlated with the highest number of clinical variables and was functionally enriched with numerous immune T-lymphocyte related pathways. This gene module identified two distinct clusters of AATD individuals with different disease severity and distinct PBMC gene expression patterns.
Conclusions We successfully identified novel clusters of AATD individuals where severity correlated with increased immune response independent of individuals’ genotype and augmentation therapy. These findings may suggest the presence of previously unrecognised disease endotypes in AATD that associate with T-lymphocyte immunity and disease severity.
- alpha1 antitrypsin deficiency
- COPD mechanisms
Statistics from Altmetric.com
Twitter @jenhwachu, @yingzezhang, @maorsauler, @kaminskimed
J-hC, WZ and MV contributed equally.
Presented at Parts of this work were presented as abstracts in American Thoracic Society International Conference in San Diego, California, May 2018.
Contributors NK, RS, FCS, SRW and CS conceived and designed the experiments. ESC, RGC, RS, CS, MJB, HH, KFG, ELH and JKL participated in subject phenotyping and classification. KCP, RGC, NK, RS, CS, EM, MB, HH, KFG, ELH, RS and SRW supervised sample and data collection, MV, TA, and GD performed the RNA sequencing experiments. JCS performed the single cell RNA sequencing experiments. JC, WZ, NK, MV, XY, BH, AM and MS analysed the data. NK, CS and FCS supervised the analytic plan. JC, WZ and MV wrote the manuscript with input from all other authors. All authors have read and approved the manuscript.
Funding This work is supported by NIH/NHLBI grant U01HL112707.
Patient consent for publication Not required.
Ethics approval The recruitment and consenting procedures were approved by the local Institutional Review Board.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available in a public, open access repository. RNAseq data described in this paper has been deposited in the NCBI Gene Expression Omnibus (GEO) under accession code GSE109515.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.